PriceTargets.com logo

Lucid Diagnostics - LUCD Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $3.94
  • Forecasted Upside: 239.44%
  • Number of Analysts: 5
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$1.16 As of 12/12/2025 05:00 PM ET
▲ +0.02 (1.75%)

This chart shows the closing price for LUCD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Lucid Diagnostics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LUCD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LUCD

Analyst Price Target is $3.94
▲ +239.44% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Lucid Diagnostics in the last 3 months. The average price target is $3.94, with a high forecast of $8.25 and a low forecast of $2.00. The average price target represents a 239.44% upside from the last price of $1.16.

This chart shows the closing price for LUCD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 5 investment analysts is to moderate buy stock in Lucid Diagnostics. This rating has held steady since September 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/21/2024
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/19/2024
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/18/2024
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/18/2025
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/16/2025
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/14/2025
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/13/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/13/2025

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/10/2025Ascendiant Capital MarketsBoost TargetBuy ➝ Buy$8.00 ➝ $8.25
12/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
11/24/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/13/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$3.00
11/5/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
10/14/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
10/6/2025Ascendiant Capital MarketsBoost TargetBuy ➝ Buy$7.75 ➝ $8.00
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/5/2025BTIG ResearchBoost TargetBuy ➝ Buy$2.00 ➝ $2.50
8/13/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$3.00
7/16/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$3.00
6/6/2025Ascendiant Capital MarketsBoost TargetBuy ➝ Buy$7.50 ➝ $7.75
5/15/2025Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$2.00 ➝ $2.00
5/14/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$3.00 ➝ $3.00
4/21/2025Ascendiant Capital MarketsBoost TargetBuy ➝ Buy$7.00 ➝ $7.50
4/11/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$3.00 ➝ $3.00
3/26/2025Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$2.00 ➝ $2.00
3/25/2025BTIG ResearchSet Target$2.00
3/24/2025Needham & Company LLCBoost TargetBuy ➝ Buy$2.50 ➝ $3.00
12/9/2024Ascendiant Capital MarketsLower TargetBuy ➝ Buy$7.25 ➝ $7.00
11/15/2024Cantor FitzgeraldLower TargetOverweight ➝ Overweight$3.00 ➝ $2.00
11/14/2024Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$3.00 ➝ $3.00
11/14/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$2.50 ➝ $2.50
9/10/2024Ascendiant Capital MarketsLower TargetBuy ➝ Buy$7.50 ➝ $7.25
8/13/2024Canaccord Genuity GroupUpgradeStrong-Buy
8/13/2024Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$3.00 ➝ $3.00
8/13/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$2.50 ➝ $2.50
6/6/2024Ascendiant Capital MarketsLower TargetBuy ➝ Buy$8.00 ➝ $7.50
5/15/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$3.00
5/13/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$2.50
4/12/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$2.50
3/27/2024Cantor FitzgeraldLower TargetOverweight ➝ Overweight$3.80 ➝ $3.00
3/27/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$2.50
11/14/2023Needham & Company LLCLower TargetBuy ➝ Buy$2.80 ➝ $2.50
9/26/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$4.00
8/22/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$4.00
8/16/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$4.00
8/16/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$2.80
5/17/2023Cantor FitzgeraldLower Target$4.50 ➝ $4.00
4/21/2023Needham & Company LLCReiterated RatingBuy$2.60
3/14/2023Needham & Company LLCLower TargetBuy$3.10 ➝ $2.60
11/18/2022BTIG ResearchLower TargetBuy$5.00 ➝ $3.50
11/15/2022Needham & Company LLCLower TargetBuy$4.25 ➝ $3.10
8/16/2022Needham & Company LLCLower TargetBuy$5.00 ➝ $4.25
6/9/2022Ascendiant Capital MarketsLower Target$13.00
5/13/2022BTIG ResearchReiterated RatingBuy$5.00
5/12/2022Canaccord Genuity GroupLower Target$12.00 ➝ $8.00
4/5/2022BTIG ResearchLower Target$14.00 ➝ $6.00
3/29/2022Canaccord Genuity GroupLower TargetBuy$18.00 ➝ $12.00
3/29/2022Needham & Company LLCLower TargetBuy$13.00 ➝ $7.00
2/4/2022Cantor FitzgeraldReiterated RatingOverweight
12/27/2021Ascendiant Capital MarketsInitiated CoverageBuy$16.00
12/15/2021Needham & Company LLCLower TargetBuy$17.00 ➝ $13.00
11/8/2021BTIG ResearchInitiated CoverageBuy$14.00
11/8/2021Cantor FitzgeraldInitiated CoverageOverweight$21.00
11/8/2021Needham & Company LLCInitiated CoverageBuy$17.00
(Data available from 12/13/2020 forward)

News Sentiment Rating

0.17 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
5/17/2025
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/16/2025
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/16/2025
  • 2 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
8/15/2025
  • 5 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/14/2025
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/14/2025
  • 5 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/13/2025
  • 1 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/13/2025

Current Sentiment

  • 1 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Lucid Diagnostics logo
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Read More

Today's Range

Now: $1.16
Low: $1.12
High: $1.17

50 Day Range

MA: $1.13
Low: $1.01
High: $1.28

52 Week Range

Now: $1.16
Low: $0.75
High: $1.80

Volume

544,433 shs

Average Volume

707,220 shs

Market Capitalization

$159.71 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.22

Frequently Asked Questions

What sell-side analysts currently cover shares of Lucid Diagnostics?

The following equities research analysts have issued reports on Lucid Diagnostics in the last twelve months: Ascendiant Capital Markets, BTIG Research, Cantor Fitzgerald, Needham & Company LLC, Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for LUCD.

What is the current price target for Lucid Diagnostics?

0 Wall Street analysts have set twelve-month price targets for Lucid Diagnostics in the last year. Their average twelve-month price target is $3.94, suggesting a possible upside of 239.4%. Ascendiant Capital Markets has the highest price target set, predicting LUCD will reach $8.25 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $2.00 for Lucid Diagnostics in the next year.
View the latest price targets for LUCD.

What is the current consensus analyst rating for Lucid Diagnostics?

Lucid Diagnostics currently has 1 sell rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for LUCD.

What other companies compete with Lucid Diagnostics?

Other companies that are similar to Lucid Diagnostics include NeuroPace, Avanos Medical, RxSight, OrthoPediatrics and Sight Sciences. Learn More about companies similar to Lucid Diagnostics.

How do I contact Lucid Diagnostics' investor relations team?

The company's listed phone number is 212-949-4319 and its investor relations email address is [email protected]. The official website for Lucid Diagnostics is www.luciddx.com. Learn More about contacing Lucid Diagnostics investor relations.